Personalised medicine for gastric cancer patients
Gastric cancer (GC) is the third leading cause of cancer death worldwide. The survival rate for patients with advanced GC is about 12 months. The EU-funded LEGACy project will improve GC outcomes by implementing actions for an earlier diagnosis and suggesting optimal treatment options according to patient characteristics. LEGACy approaches personalised medicine at the three levels of prevention in the central and eastern Europe, and in Central and South America, analysing the reasons for the diagnosis delay as well as an integral analysis of the epidemiological facts correlated with the multi-omic profile of these patients. Finally, the project will train young researchers and educate the general population on GC risk factors and symptoms.
Fields of science
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action
C1426NZ Buenos Aires